Regulation of Long Non-Coding RNAs by Plant Secondary Metabolites: A Novel Anticancer Therapeutic Approach

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Apr 3

PMID 33805687

Citations 15

Authors

Mohammad Reza Kalhori

Hamid Khodayari

Saeed Khodayari

Miko Vesovic

Gloria Jackson

Mohammad Hosein Farzaei

Anupam Bishayee

Affiliations

Soon will be listed here.

Abstract

Long non-coding RNAs (lncRNAs) are a class of non-coding RNAs that play an essential role in various cellular activities, such as differentiation, proliferation, and apoptosis. Dysregulation of lncRNAs serves a fundamental role in the progression and initiation of various diseases, including cancer. Precision medicine is a suitable and optimal treatment method for cancer so that based on each patient's genetic content, a specific treatment or drug is prescribed. The rapid advancement of science and technology in recent years has led to many successes in this particular treatment. Phytochemicals are a group of natural compounds extracted from fruits, vegetables, and plants. Through the downregulation of oncogenic lncRNAs or upregulation of tumor suppressor lncRNAs, these bioactive compounds can inhibit metastasis, proliferation, invasion, migration, and cancer cells. These natural products can be a novel and alternative strategy for cancer treatment and improve tumor cells' sensitivity to standard adjuvant therapies. This review will discuss the antineoplastic effects of bioactive plant secondary metabolites (phytochemicals) via regulation of expression of lncRNAs in various human cancers and their potential for the treatment and prevention of human cancers.

Citing Articles

Long non-coding RNA involved in the carcinogenesis of human female cancer - a comprehensive review.

Afroze N, Sundaram M, Haque S, Hussain A Discov Oncol. 2025; 16(1):122.

PMID: 39912983 PMC: 11803034. DOI: 10.1007/s12672-025-01848-1.

Diagnostic and therapeutic role of non-coding RNAs regulating programmed cell death in melanoma.

Wang Z, Xie C, Chen X Front Oncol. 2025; 14():1476684.

PMID: 39777348 PMC: 11703721. DOI: 10.3389/fonc.2024.1476684.

Human disease-related long noncoding RNAs: Impact of ginsenosides.

Jang S, Lee H, Kim H, Baek M, Jung S, Kim S J Ginseng Res. 2024; 48(4):347-353.

PMID: 39036728 PMC: 11258377. DOI: 10.1016/j.jgr.2024.04.002.

Genome editing approaches with CRISPR/Cas9: the association of NOX4 expression in breast cancer patients and effectiveness evaluation of different strategies of CRISPR/Cas9 to knockout Nox4 in cancer cells.

Javadi M, Sazegar H, Doosti A BMC Cancer. 2023; 23(1):1155.

PMID: 38012557 PMC: 10683234. DOI: 10.1186/s12885-023-11183-9.

Strategic and Innovative Roles of lncRNAs Regulated by Naturally-derived Small Molecules in Cancer Therapy.

Alkan A, Ensoy M, Cansaran-Duman D Curr Med Chem. 2023; 31(40):6672-6691.

PMID: 37921177 DOI: 10.2174/0109298673264372230919102758.

References

Zhang J, Liu J, Xu X, Li L . Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer. Cancer Chemother Pharmacol. 2017; 79(3):479-487. DOI: 10.1007/s00280-017-3238-4. View

Xue M, Li X, Li Z, Chen W . Urothelial carcinoma associated 1 is a hypoxia-inducible factor-1α-targeted long noncoding RNA that enhances hypoxic bladder cancer cell proliferation, migration, and invasion. Tumour Biol. 2014; 35(7):6901-12. DOI: 10.1007/s13277-014-1925-x. View

Shi B, Wang Y, Yin F . MALAT1/miR-124/Capn4 axis regulates proliferation, invasion and EMT in nasopharyngeal carcinoma cells. Cancer Biol Ther. 2017; 18(10):792-800. PMC: 5678686. DOI: 10.1080/15384047.2017.1373214. View

Chen A, Jiang P, Zeb F, Wu X, Xu C, Chen L . EGCG regulates CTR1 expression through its pro-oxidative property in non-small-cell lung cancer cells. J Cell Physiol. 2020; 235(11):7970-7981. DOI: 10.1002/jcp.29451. View

Beaver L, Kuintzle R, Buchanan A, Wiley M, Glasser S, Wong C . Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer. J Nutr Biochem. 2017; 42:72-83. PMC: 5360475. DOI: 10.1016/j.jnutbio.2017.01.001. View

Wu Q, Lian J, Stein J, Stein G, Nickerson J, Imbalzano A . The BRG1 ATPase of human SWI/SNF chromatin remodeling enzymes as a driver of cancer. Epigenomics. 2017; 9(6):919-931. PMC: 5705788. DOI: 10.2217/epi-2017-0034. View

Schmitz S, Grote P, Herrmann B . Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 2016; 73(13):2491-509. PMC: 4894931. DOI: 10.1007/s00018-016-2174-5. View

DU Q, Peng C, Zhang H . Polydatin: a review of pharmacology and pharmacokinetics. Pharm Biol. 2013; 51(11):1347-54. DOI: 10.3109/13880209.2013.792849. View

Kang K, Piao M, Hyun Y, Zhen A, Cho S, Ahn M . Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells. Exp Mol Med. 2019; 51(4):1-14. PMC: 6465248. DOI: 10.1038/s12276-019-0238-y. View

10.

Deep G, Agarwal R . Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010; 29(3):447-63. PMC: 3928361. DOI: 10.1007/s10555-010-9237-0. View

11.

Tomita S, Abdalla M, Fujiwara S, Matsumori H, Maehara K, Ohkawa Y . A cluster of noncoding RNAs activates the ESR1 locus during breast cancer adaptation. Nat Commun. 2015; 6:6966. PMC: 4421845. DOI: 10.1038/ncomms7966. View

12.

Tian J, Wang Y, Zhang X, Ren Q, Li R, Huang Y . Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling. J Exp Clin Cancer Res. 2017; 36(1):153. PMC: 5667511. DOI: 10.1186/s13046-017-0625-y. View

13.

Cabili M, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A . Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011; 25(18):1915-27. PMC: 3185964. DOI: 10.1101/gad.17446611. View

14.

Anand P, Sundaram C, Jhurani S, Kunnumakkara A, Aggarwal B . Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 2008; 267(1):133-64. DOI: 10.1016/j.canlet.2008.03.025. View

15.

Liang W, Fu W, Wong C, Wang Y, Wang W, Hu G . The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget. 2015; 6(26):22513-25. PMC: 4673179. DOI: 10.18632/oncotarget.4154. View

16.

Collins F, Varmus H . A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5. PMC: 5101938. DOI: 10.1056/NEJMp1500523. View

17.

Li G, Zhu Y . Effect of lncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro. Pathol Res Pract. 2019; 215(5):931-938. DOI: 10.1016/j.prp.2019.01.042. View

18.

Kong L, Li X, Wang H, He G, Tang A . Calycosin inhibits nasopharyngeal carcinoma cells by influencing EWSAT1 expression to regulate the TRAF6-related pathways. Biomed Pharmacother. 2018; 106:342-348. DOI: 10.1016/j.biopha.2018.06.143. View

19.

Ho T, Huang J, Zhou N, Zhang Z, Koirala P, Zhou X . Regulation of PCGEM1 by p54/nrb in prostate cancer. Sci Rep. 2016; 6:34529. PMC: 5041109. DOI: 10.1038/srep34529. View

20.

Tan Y, Tang L, Ouyang W, Jiang T, Zhang H, Li S . β-catenin-coordinated lncRNA MALAT1 up-regulation of ZEB-1 could enhance the telomerase activity in HGF-mediated differentiation of bone marrow mesenchymal stem cells into hepatocytes. Pathol Res Pract. 2019; 215(3):546-554. DOI: 10.1016/j.prp.2019.01.002. View